Unlocking biomarker discovery: Large scale application of aptamer proteomic technology for early detection of lung cancer

PLoS ONE

Volumn 5, Issue 12, 2010, Pages

  Ostroff, Rachel M ^a   Bigbee, William L ^b   Franklin, Wilbur ^c   Gold, Larry ^a,d   Mehan, Mike ^a   Miller, York E ^c,e   Pass, Harvey I ^f   Rom, William N ^f   Siegfried, Jill M ^b   Stewart, Alex ^a   Walker, Jeffrey J ^a   Weissfeld, Joel L ^b   Williams, Stephen ^a   Zichi, Dom ^a   Brody, Edward N ^a  

^a SomaLogic Inc   (United States)

^b UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^c UNIVERSITY OF COLORADO CANCER CENTER   (United States)

^d UNIVERSITY OF COLORADO   (United States)

^e VETERANS AFFAIRS MEDICAL CENTER   (United States)

^f NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APTAMER; BIOLOGICAL MARKER; BLOOD CLOTTING FACTOR 9; BONE MORPHOGENETIC PROTEIN; BONE MORPHOGENETIC PROTEIN 14; CADHERIN; CADHERIN 1; CD30 LIGAND; COAGULATION FACTOR IXAB; COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C3A; COMPLEMENT COMPONENT C3B; DNA APTAMER; ENDOSTATIN; HEAT SHOCK PROTEIN 90; HEAT SHOCK PROTEIN 90ALPHA; HEMOJUVELIN; L SELECTIN; MONOKINE; PLEIOTROPHIN; PROTEIN KINASE YES; PROTEIN LRIG3; PROTEIN MIP 4; PROTEIN PRKCI; PROTEIN SCF RECEPTOR; PROTEIN SERINE THREONINE KINASE; REAGENT; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG; AUTOANTIBODY; TUMOR MARKER;

ADULT; AGE; AGED; AIRWAY OBSTRUCTION; AMINO ACID SEQUENCE; ANALYTIC METHOD; ARTICLE; BAYES THEOREM; BIOTECHNOLOGY; CANCER STAGING; CHRONIC OBSTRUCTIVE LUNG DISEASE; CIGARETTE SMOKING; CLASSIFICATION ALGORITHM; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DOWN REGULATION; EARLY DIAGNOSIS; FEMALE; HUMAN; LARGE CELL CARCINOMA; LUNG ADENOCARCINOMA; LUNG NODULE; LUNG NON SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; POPULATION BASED CASE CONTROL STUDY; PROTEIN BINDING; PROTEIN BLOOD LEVEL; QUANTITATIVE ASSAY; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; UPREGULATION; VALIDATION PROCESS; ALGORITHM; CASE CONTROL STUDY; CHEMISTRY; CLINICAL TRIAL; COHORT ANALYSIS; LUNG TUMOR; MASS SPECTROMETRY; METABOLISM; METHODOLOGY; MULTICENTER STUDY; PROTEOMICS; SMOKING; STATISTICAL MODEL;

NICOTIANA TABACUM;

ALGORITHMS; AUTOANTIBODIES; BIOLOGICAL MARKERS; CARCINOMA, NON-SMALL-CELL LUNG; CASE-CONTROL STUDIES; COHORT STUDIES; EARLY DETECTION OF CANCER; HUMANS; LUNG NEOPLASMS; MASS SPECTROMETRY; MODELS, STATISTICAL; PROTEOMICS; SENSITIVITY AND SPECIFICITY; SMOKING; TUMOR MARKERS, BIOLOGICAL;

EID: 78650121234     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0015003     Document Type: Article

References (60)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, et al. (2009) Cancer statistics, 2009. CA Cancer J Clin 59: 225-249.
2. Okada M, Nishio W, Sakamoto T, Uchino K, Yuki T, et al. (2005) Effect of tumor size on prognosis in patients with non-small cell lung cancer: the role of segmentectomy as a type of lesser resection. J Thorac Cardiovasc Surg 129: 87-93.
3. Kassis ES, Vaporciyan AA, Swisher SG, Correa AM, Bekele BN, et al. (2009) Application of the revised lung cancer staging system (IASLC Staging Project) to a cancer center population. J Thorac Cardiovasc Surg 138: 412-418 e411-412.
4. (2008) World Cancer Report; Boyle P, Levin B, eds. Lyon: International Agency for Research on Cancer (IARC).
5. Wilson DO, Weissfeld JL, Fuhrman CR, Fisher SN, Balogh P, et al. (2008) The Pittsburgh Lung Screening Study (PLuSS): outcomes within 3 years of a first computed tomography scan. Am J Respir Crit Care Med 178: 956-961.
6. Black WC (2007) Computed tomography screening for lung cancer: review of screening principles and update on current status. Cancer 110: 2370-2384.
7. Yau G, Lock M, Rodrigues G (2007) Systematic review of baseline low-dose CT lung cancer screening. Lung Cancer 58: 161-170.
8. NLST (2009) National Lung Screening Trial, http://www.cancer.gov/nlst.
9. Smith RA, Cokkinides V, Eyre HJ (2007) Cancer screening in the United States, 2007: a review of current guidelines, practices, and prospects. CA Cancer J Clin 57: 90-104.
10. Blanchon T, Brechot JM, Grenier PA, Ferretti GR, Lemarie E, et al. (2007) Baseline results of the Depiscan study: a French randomized pilot trial of lung cancer screening comparing low dose CT scan (LDCT) and chest X-ray (CXR). Lung Cancer 58: 50-58.
11. Infante M, Lutman FR, Cavuto S, Brambilla G, Chiesa G, et al. (2008) Lung cancer screening with spiral CT: baseline results of the randomized DANTE trial. Lung Cancer 59: 355-363.
12. van Iersel CA, de Koning HJ, Draisma G, Mali WP, Scholten ET, et al. (2007) Risk-based selection from the general population in a screening trial: selection criteria, recruitment and power for the Dutch-Belgian randomised lung cancer multi-slice CT screening trial (NELSON). Int J Cancer 120: 868-874.
13. van Klaveren RJ, Oudkerk M, Prokop M, Scholten ET, Nackaerts K, et al. (2009) Management of lung nodules detected by volume CT scanning. N Engl J Med 361: 2221-2229.
14. Pinsky PF, Marcus PM, Kramer BS, Freedman M, Nath H, et al. (2005) Diagnostic procedures after a positive spiral computed tomography lung carcinoma screen. Cancer 103: 157-163.
15. Welch HG, Woloshin S, Schwartz LM, Gordis L, Gotzsche PC, et al. (2007) Overstating the evidence for lung cancer screening: the International Early Lung Cancer Action Program (I-ELCAP) study. Arch Intern Med 167: 2289-2295.
16. Brenner DJ (2004) Radiation risks potentially associated with low-dose CT screening of adult smokers for lung cancer. Radiology 231: 440-445.
17. Brower V (2009) Biomarker studies abound for early detection of lung cancer. J Natl Cancer Inst 101: 11-13.
18. Gold L, Ayers D, Bertino J, Bock A, Bock C, et al. (2010) Aptamer-based multiplexed proteomic technology for biomarker discovery. PLoS ONE 5(11): e15004. doi: 10.1371/journal.pone.0015004.
19. Hartwell L, Mankoff D, Paulovich A, Ramsey S, Swisher E (2006) Cancer biomarkers: a systems approach. Nat Biotechnol 24: 905-908.
20. Rifai N, Gillette MA, Carr SA (2006) Protein biomarker discovery and validation: the long and uncertain path to clinical utility. Nat Biotechnol 24: 971-983.
21. Pepe MS, Feng Z, Janes H, Bossuyt PM, Potter JD (2008) Pivotal evaluation of the accuracy of a biomarker used for classification or prediction: standards for study design. J Natl Cancer Inst 100: 1432-1438.
22. Tuck MK, Chan DW, Chia D, Godwin AK, Grizzle WE, et al. (2009) Standard operating procedures for serum and plasma collection: early detection research network consensus statement standard operating procedure integration working group. J Proteome Res 8: 113-117.
23. Ransohoff DF, Gourlay ML (2010) Sources of bias in specimens for research about molecular markers for cancer. J Clin Oncol 28: 698-704.
24. Greenberg AK, Rimal B, Felner K, Zafar S, Hung J, et al. (2007) Sadenosylmethionine as a biomarker for the early detection of lung cancer. Chest 132: 1247-1252.
25. Ambrosone CB, Nesline MK, Davis W (2006) Establishing a cancer center data bank and biorepository for multidisciplinary research. Cancer Epidemiol Biomarkers Prev 15: 1575-1577.
26. Keeney T, Kraemer S, Walker JJ, Bock C, Vaught J, et al. (2009) Automation of the SomaLogic Proteomics Assay: A Platform for Biomarker Discovery. J Assoc Lab Automat 14: 360-366.
27. Duda O, Hart PE, Stork DG (2001) Pattern Classification. New York: John Wiley and Sons.
28. Ostroff R, Foreman T, Keeney TR, Stratford S, Walker JJ, et al. (2009) The stability of the circulating human proteome to variations in sample collection and handling procedures measured with an aptamer-based proteomics array. J Proteomics.
29. Zhang Z, Chan DW (2005) Cancer proteomics: in pursuit of "true" biomarker discovery. Cancer Epidemiol Biomarkers Prev 14: 2283-2286.
30. Chen G, Wang X, Yu J, Varambally S, Thomas DG, et al. (2007) Autoantibody profiles reveal ubiquilin 1 as a humoral immune response target in lung adenocarcinoma. Cancer Res 67: 3461-3467.
31. Zhong L, Hidalgo GE, Stromberg AJ, Khattar NH, Jett JR, et al. (2005) Using protein microarray as a diagnostic assay for non-small cell lung cancer. Am J Respir Crit Care Med 172: 1308-1314.
32. Gao WM, Kuick R, Orchekowski RP, Misek DE, Qiu J, et al. (2005) Distinctive serum protein profiles involving abundant proteins in lung cancer patients based upon antibody microarray analysis. BMC Cancer 5: 110.
33. Sung HJ, Cho JY (2008) Biomarkers for the lung cancer diagnosis and their advances in proteomics. BMB Rep 41: 615-625.
34. Greenberg AK, Lee MS (2007) Biomarkers for lung cancer: clinical uses. Curr Opin Pulm Med 13: 249-255.
35. Cioffi M, Gazzerro P, Di Finizio B, Vietri MT, Di Macchia C, et al. (1999) Serum-soluble E-cadherin fragments in lung cancer. Tumori 85: 32-34.
36. Iizasa T, Chang H, Suzuki M, Otsuji M, Yokoi S, et al. (2004) Overexpression of collagen XVIII is associated with poor outcome and elevated levels of circulating serum endostatin in non-small cell lung cancer. Clin Cancer Res 10: 5361-5366.
37. Xu A, Tian T, Hao J, Liu J, Zhang Z, et al. (2007) Elevation of serum HSP90a correlated with the clinical stage of non-small cell lung cancer. J Cancer Mol 3: 107-112.
38. Jager R, List B, Knabbe C, Souttou B, Raulais D, et al. (2002) Serum levels of the angiogenic factor pleiotrophin in relation to disease stage in lung cancer patients. Br J Cancer 86: 858-863.
39. Suzuki M, Iizasa T, Ko E, Baba M, Saitoh Y, et al. (2002) Serum endostatin correlates with progression and prognosis of non-small cell lung cancer. Lung Cancer 35: 29-34.
40. Banerji U (2009) Heat shock protein 90 as a drug target: some like it hot. Clin Cancer Res 15: 9-14.
41. Gancz D, Fishelson Z (2009) Cancer resistance to complement-dependent cytotoxicity (CDC): Problem-oriented research and development. Mol Immunol 46: 2794-2800.
42. Schutyser E, Richmond A, Van Damme J (2005) Involvement of CC chemokine ligand 18 (CCL18) in normal and pathological processes. J Leukoc Biol 78: 14-26.
43. Erdogan E, Klee EW, Thompson EA, Fields AP (2009) Meta-analysis of oncogenic protein kinase Ciota signaling in lung adenocarcinoma. Clin Cancer Res 15: 1527-1533.
44. Nonomura T, Masaki T, Morishita A, Jian G, Uchida N, et al. (2007) Identification of c-Yes expression in the nuclei of hepatocellular carcinoma cells: involvement in the early stages of hepatocarcinogenesis. Int J Oncol 30: 105-111.
45. Ceteci F, Ceteci S, Karreman C, Kramer BW, Asan E, et al. (2007) Disruption of tumor cell adhesion promotes angiogenic switch and progression to micrometastasis in RAF-driven murine lung cancer. Cancer Cell 12: 145-159.
46. Charalabopoulos K, Gogali A, Kostoula OK, Constantopoulos SH (2004) Cadherin superfamily of adhesion molecules in primary lung cancer. Exp Oncol 26: 256-260.
47. Cai M, Han L, Chen R, Ye F, Wang B, et al. (2009) Inhibition of LRIG3 gene expression via RNA interference modulates the proliferation, cell cycle, cell apoptosis, adhesion and invasion of glioblastoma cell (GL15). Cancer Lett 278: 104-112.
48. Hanson EM, Clements VK, Sinha P, Ilkovitch D, Ostrand-Rosenberg S (2009) Myeloid-derived suppressor cells down-regulate L-selectin expression on CD4+ and CD8+ T cells. J Immunol 183: 937-944.
49. Turner AM, Bennett LG, Lin NL, Wypych J, Bartley TD, et al. (1995) Identification and characterization of a soluble c-kit receptor produced by human hematopoietic cell lines. Blood 85: 2052-2058.
50. Babitt JL, Huang FW, Wrighting DM, Xia Y, Sidis Y, et al. (2006) Bone morphogenetic protein signaling by hemojuvelin regulates hepcidin expression. Nat Genet 38: 531-539.
51. Babitt JL, Huang FW, Xia Y, Sidis Y, Andrews NC, et al. (2007) Modulation of bone morphogenetic protein signaling in vivo regulates systemic iron balance. J Clin Invest 117: 1933-1939.
52. Ward DG, Roberts K, Brookes MJ, Joy H, Martin A, et al. (2008) Increased hepcidin expression in colorectal carcinogenesis. World J Gastroenterol 14: 1339-1345.
53. Yildiz PB, Shyr Y, Rahman JS, Wardwell NR, Zimmerman LJ, et al. (2007) Diagnostic accuracy of MALDI mass spectrometric analysis of unfractionated serum in lung cancer. J Thorac Oncol 2: 893-901.
54. Patz EF, Jr., Campa MJ, Gottlin EB, Kusmartseva I, Guan XR, et al. (2007) Panel of serum biomarkers for the diagnosis of lung cancer. J Clin Oncol 25: 5578-5583.
55. Spira A, Beane JE, Shah V, Steiling K, Liu G, et al. (2007) Airway epithelial gene expression in the diagnostic evaluation of smokers with suspect lung cancer. Nat Med 13: 361-366.
56. Diederich S, Thomas M, Semik M, Lenzen H, Roos N, et al. (2004) Screening for early lung cancer with low-dose spiral computed tomography: results of annual follow-up examinations in asymptomatic smokers. Eur Radiol 14: 691-702.
57. Swensen SJ, Jett JR, Sloan JA, Midthun DE, Hartman TE, et al. (2002) Screening for lung cancer with low-dose spiral computed tomography. Am J Respir Crit Care Med 165: 508-513.
58. Croswell JM, Kramer BS, Kreimer AR, Prorok PC, Xu JL, et al. (2009) Cumulative incidence of false-positive results in repeated, multimodal cancer screening. Ann Fam Med 7: 212-222.
59. Twombly R (2010) Federal oversight of medical radiation is on horizon as experts face off. J Natl Cancer Inst 102: 514-515.
60. GOLD (2008) The Global Strategy for Diagnosis, Management and Prevention of COPD; www.goldcopd.org.